Track AKTX in your personal workspace
Monitor performance, SPY relative strength
and WOI View from your watchlist.
Alert me when AKTX price is:
52W Range Position
11%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 14:46 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Insufficient / Insufficient
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
10.46
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUN
26
↗
Equity Offering / Capital Raise
MEDIUM
AKTX equity financing update
As previously disclosed on its Current Report on Form 8-K on May 22, 2026, Akari Therapeutics, Plc (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain investors (the “ Investors ”), pursuant to which the Company agreed to sell and issue in a private placement (the...
As previously disclosed on its Current Report on Form 8-K on May 22, 2026, Akari Therapeutics, Plc (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain investors (the “ Investors ”), pursuant to which the Company agreed to sell and issue in a private placement (the “ Offering ”) an aggregate of 1,470,588 unregistered American Depository Shares (“ ADSs ”), or prefunded warrants to purchase ADSs, each representing 80,000 of the Company’s ordinary shares per ADS, together with Series H warrants, Series I warrants and Series J warrants to purchase an equivalent number of ADSs (the Series H, Series I, and Series J warrants collectively referred to as the “ Series Warrants ”).
8-K Filing•SEC EDGAR
JUN
26
●
Material Agreement
MEDIUM
AKTX material agreement
As previously disclosed on its Current Report on Form 8-K on May 22, 2026, Akari Therapeutics, Plc (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain investors (the “ Investors ”), pursuant to which the Company agreed to sell and issue in a private placement (the...
As previously disclosed on its Current Report on Form 8-K on May 22, 2026, Akari Therapeutics, Plc (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain investors (the “ Investors ”), pursuant to which the Company agreed to sell and issue in a private placement (the “ Offering ”) an aggregate of 1,470,588 unregistered American Depository Shares (“ ADSs ”), or prefunded warrants to purchase ADSs, each representing 80,000 of the Company’s ordinary shares per ADS, together with Series H warrants, Series I warrants and Series J warrants to purchase an equivalent number of ADSs (the Series H, Series I, and Series J warrants collectively referred to as the “ Series Warrants ”).
8-K Filing•SEC EDGAR
MAY
22
●
Material Agreement
MEDIUM
AKTX material agreement
On May 20, 2026, Akari Therapeutics, Plc (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain investors, pursuant to which the Company agreed to sell and issue in a private placement (the “ Offering ”) an aggregate of 1,470,588 unregistered American Depository Shar...
On May 20, 2026, Akari Therapeutics, Plc (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain investors, pursuant to which the Company agreed to sell and issue in a private placement (the “ Offering ”) an aggregate of 1,470,588 unregistered American Depository Shares (“ ADSs ”), each representing 80,000 of the Company’s ordinary shares (the “ Shares ”), or prefunded warrants in lieu thereof (“ Pre-Funded Warrants ”), and, in each case, Series H warrants to purchase ADS (“ Series H Warrants ”), Series I warrants to purchase ADS (“ Series I Warrants ”) and Series J warrants to purchase ADS (“ Series J Warrants ”, together with the Pre-Funded Warrants, the Series H Warrants and the Series I Warrants, the “ Warrants, ” and together with the ADSs or Pre-Funded Warrants, the “ Units ”).
8-K Filing•SEC EDGAR
What's Driving AKTX?
📈 Technical recovery is improving
Momentum is Neutral. Watch 10.46 for confirmation and — for structure risk.